We provide you with 20 years of free, institutional-grade data for ZYME stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of ZYME. Explore the full financial landscape of ZYME stock.
| Reported Date | CIK | Ticker | Type | |
|---|---|---|---|---|
| 2025-08-07 | 1937653 | ZYME | 10-Q | Url |
| 2025-05-08 | 1937653 | ZYME | 10-Q | Url |
| 2025-03-05 | 1937653 | ZYME | 10-K | Url |
| 2024-10-31 | 1937653 | ZYME | 10-Q | Url |
| 2024-08-01 | 1937653 | ZYME | 10-Q | Url |
| 2024-05-02 | 1937653 | ZYME | 10-Q | Url |
| 2024-03-06 | 1937653 | ZYME | 10-K | Url |
| 2023-11-07 | 1937653 | ZYME | 10-Q | Url |
| 2023-08-10 | 1937653 | ZYME | 10-Q | Url |
| 2023-05-08 | 1937653 | ZYME | 10-Q | Url |
| 2023-03-07 | 1937653 | ZYME | 10-K | Url |
| 2022-11-08 | 1937653 | ZYME | 10-Q | Url |
Zymeworks Inc(NASDAQ:ZYME) 
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of ...
Website: http://www.zymeworks.com
Founded: 2003
Full Time Employees: 325
Sector: Healthcare
Industry: Biotechnology
The information provided in this report about ZYME stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.